Samsung and MGH Launch Galaxy Watch GLP-1 Muscle Loss Study
Samsung Electronics has partnered with the Massachusetts General Hospital Diabetes Research Center to launch a Galaxy Watch GLP-1 muscle loss study. The clinical research, announced on May 28, 2026, focuses on individuals starting GLP-1 receptor agonist therapies, such as those used for weight management and diabetes, to determine if wearable technology can improve health outcomes.
The joint study involves 100 adult participants split into two groups. One group will use a Galaxy Watch equipped with a BioActive Sensor to track their body composition, while a control group receives standard medical care. Those in the intervention group will have access to personalized exercise routines and regular body monitoring through Bioelectrical Impedance Analysis (BIA) on their wrist.
A primary concern with rapid weight loss from GLP-1 drugs is the simultaneous loss of lean muscle mass. Samsung aims to verify if the BIA technology in its smartwatches provides accurate enough data for clinicians to make informed care adjustments. To ensure precision, researchers will compare the wearable data against clinical-grade DXA scans, which are the industry standard for measuring body fat and muscle.
By providing users with real-time biometric feedback and guided physical activity, the program seeks to encourage sustainable health habits. Samsung stated that the goal is to offer a more holistic view of a patient's health, allowing for data-driven interventions that go beyond simple weight tracking. This research could expand the role of consumer wearables in formal medical treatments for metabolic health.
While we strive for accuracy, bytevyte can make mistakes. Users are advised to verify all information independently. We accept no liability for errors or omissions.
Sources
AI-generated image.
Related Articles
✔Human Verified